| Description | Lp-PLA2-IN-1 (Lp-PLA2 inhibitor 1) suppresses Lp-PLA2 activity processes for their preparation. Lp-PLA2-IN-1 (Lp-PLA2 inhibitor 1) also inhibits to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example, atherosclerosis, Alzheimer's disease. |
| In vitro | Lp-PLA2 is a phospholipase A2 enzyme involved in the hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2 travels with LDL and rapidly cleaves oxidized phosphatidylcholine molecules derived from the oxidation of LDL[1]. |
| Synonyms | Lp-PLA2 inhibitor 1, Lp-PLA2 -IN-1 |
| molecular weight | 468.38 |
| Molecular formula | C21H17F5N4O3 |
| CAS | 1420367-28-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | Ethanol: 20 mg/mL (42.7 mM), Sonication is recommended. |
| References | 1. Zehong Wan, et al. Bicyclic pyrimidone compounds. WO2013014185A1. |